LOS ANGELES, CA / ACCESSWIRE / September 27, 2016 / Lundin Law PC (the “Firm”) announces a class action has been filed against MGT Capital Investments, Inc. (“MGT” or the “Company”) (NYSE MKT: MGT) concerning possible violations of federal securities laws between May 9, 2016 and September 20, 2016 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the November 21, 2016 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The complaint alleges that MGT made false and/or misleading statements and/or failed to disclose the risk that its stock to be issued in connection with the acquisitions of D-Vasive and Demonsaw may not be listed by the New York Stock Exchange (“NYSE”); and that MGT was under inquiry by the U.S. Securities and Exchange Commission (“SEC”) prior to September 19, 2016. On September 19, 2016, MGT announced that it received a subpoena from the SEC requesting information, and that it received a notification from the NYSE that the exchange would not approve the listing of the 43.8 million shares that MGT is required to issue in order to complete the D-Vasive merger. When this news was announced, shares of MGT declined in value, causing investors harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 446085

LOS ANGELES, CA / ACCESSWIRE / September 27, 2016 / Lundin Law PC (the “Firm”) announces the filing of a class action lawsuit against Polaris Industries Inc. (“Polaris” or the “Company”) (NYSE: PII) concerning possible violations of federal securities laws between January 26, 2016 and September 11, 2016 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the November 15, 2016 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The complaint alleges that during the Class Period, Polaris made false and/or misleading statements and/or failed to disclose that: Polaris was unable to sufficiently validate the initially identified repair for certain of its recalled RZR vehicles; that the Company would ultimately need to implement a more complex and expensive repair solution; that the financial impact of RZR vehicle recalls was greater than the Company had disclosed to investors; that Polaris overstated its full-year 2016 guidance; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times.

On September 12, 2016, Polaris lowered its earnings guidance range for the full year 2016. The lower guidance is related to the impact of the Company’s stop-ride/stop-sale advisory on July 25, 2016 pending a formal recall for the MY2016 RZR Turbo off-road vehicles due to potential fire hazard. When the news emerged to the public, Polaris shares fell in value, causing investors harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 446084

LOS ANGELES, CA / ACCESSWIRE / September 27, 2016 / Lundin Law PC (the “Firm”) announces the filing of a class action lawsuit against Keryx Biopharmaceuticals Inc. (“Keryx” or the “Company”) (Nasdaq: KERX) concerning possible violations of federal securities laws between February 25, 2016 and August 1, 2016 (the “Class Period”). Investors, who purchased or otherwise acquired shares during the Class Period, should contact the Firm in advance of the October 3, 2016 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The complaint alleges that in the Class Period, Keryx made false and misleading statements and/or failed to disclose: that the Company was experiencing production-related difficulties in converting API to finished drug product; that the issue was resulting in decreased production yields of finished drug product; that the Company exhausted its reserve of finished drug product; and as a result of the above, Keryx’s statements about its business, operations and prospects were false and misleading and/or lacked a reasonable basis at all relevant times. When the true details emerged to the public, the stock price of Keryx decreased, thus causing investors harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 446083

IRVINE, CA / ACCESSWIRE / September 27, 2016 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Tokai Pharmaceuticals, Inc. (“Tokai” or the “Company”) (Nasdaq: TKAI). Investors who purchased or otherwise acquired shares between June 24, 2015 and July 25, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the September 30, 2016 lead plaintiff motion deadline.

If you purchased shares of Tokai during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The complaint alleges that during the Class Period, Tokai made false and misleading statements and/or failed to disclose that: there were significant structural problems with the trial design for its Phase 3 galeterone study, ARMOR3-SV; that ARMOR3-SV was unlikely to succeed in meeting its primary endpoint; the commercialization of galeterone was less likely than investors were led to believe; and as a result of the above, the Company’s statements about its business, operations, and prospects were false and misleading at all relevant times.

If you want to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 446082

NEW YORK, NY / ACCESSWIRE / September 27, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased EndoChoice Holdings, Inc. (“EndoChoice”) (NYSE: GI) stock prior to September 27, 2016.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of EndoChoice to Boston Scientific Corporation (NYSE: BSX) for $8.00 per share. To learn more about the action and your rights, go to:

http://zlk.9nl.com/endochoice-gi

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, California, and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 446081

VANCOUVER, BC / ACCESSWIRE / September 27, 2016 / Minaurum Gold Inc. (TSXV: MGG) (“Minaurum”) is pleased to announce the results of initial rock sampling and the commencement of an exploration program at its La Quintera Silver Project.

Historical exploration work on the project included taking 334 rock samples of which 97 assayed 100-1,380 grams per tonne (“g/t”) Silver (“Ag”) and 106 returned values 30 – 100 g/t Ag. Minaurum’s initial sampling confirmed the prior range of high-grade assay results along with the addition of significant base metal grades. Highlights include: 1.0 metre of 1,020 g/tsilver, 1.11% copper, and 0.52% zinc; 2 metres of 427 g/t silver, 0.33% leadand 0.42% zinc; and 2.5m of 232 g/t silver, 1.24% lead and 0.43% zinc.

Minaurum has also commenced an extensive exploration program including the survey of old mine workings, detailed geologic mapping, rock sampling, and the interpretation of structural geology and geochemical zonation.

“We are very pleased to receive high grade results right at the outset of our initial sampling program at La Quintera,” stated Darrell Rader, President and CEO. “We have now commenced an exploration program to locate further high grade silver zones and to define drill targets.”

Table 1. Initial sampling collected at La Quintera by Minaurum.

Samp
No
Sample
Type
Width
(m)
Ag g/t
Au g/t
Cu%
Pb%
Zn%
*AgEq
g/t
100398
Outcrop
2
90
0.001
0.02
0.01
0.07
94
100400
Outcrop
 
130
0.037
0.31
0.57
0.48
184
101099
Outcrop
2
139
0.079
0.14
0.19
0.51
176
101129
Outcrop
2
427
0.096
0.32
0.33
0.42
478
101130
Outcrop
1.2
101
0.054
0.28
0.03
0.02
125
101131
Dump
1
400
0.462
1.08
1.22
8.5
815
101133
Adit
2.5
232
0.02
0.58
1.24
0.43
320
101135
Adit
 1
1020
0.032
1.11
0.19
0.52
1118

*AgEq values calculated on basis of USD prices: Ag: $19.70/troz, Au: $1,345/troz, Cu: $2.10/lb, Pb: $0.86/lb, Zn: $1.04/lb.

La Quintera is 45 km northwest of Pan American’s Alamo Dorado silver mine, and 15 km south of Cobre Del Mayo’s Piedras Verdes copper mine. The project hosts a high-grade epithermal vein system, which is estimated to have produced in excess of 120 Moz of silver from 1680 to the early 1900s from several historic mines. The project has excellent infrastructure and is fully permitted from exploration through production.

Stephen R. Maynard, Vice President of Exploration of Minaurum and a Qualified Person as defined by National Instrument 43-101, collected the samples listed in this report (except for those stated as being historical), reviewed and verified the assay data and has approved the disclosure in this News Release. The listed samples were personally sealed and delivered to the ALS Chemex sample-preparation facility in Hermosillo, Sonora, Mexico. ALS Chemex prepared the samples, crushing them to 70% less than 2mm, splitting off 250g, and pulverizing the split to more than 85% passing 75 microns. The resulting sample pulps were then sent to ALS Chemex’s analytical laboratory in North Vancouver, BC, Canada for assay. Analysis was done for 48-elements (including silver) by a 4-acid digestion and inductively coupled plasma atomic emission spectroscopy (ICP-AES). Sample pulps with silver values greater than 100 g/t; and copper, lead, or zinc values greater than 10,000 ppm (1%) were re-analyzed using 4-acid digestion and atomic absorption spectrometry (AAS). Samples were analyzed for gold using fire assay and ICP-AES.

Minaurum Gold is a regional explorer focusing on the exploration and development of high-grade gold and silver projects in Mexico. The Company is led by an experienced exploration and finance team credited with several district-scale discoveries. For more information, please visit our website at www.minaurum.com and our YouTube Minaurum Video Channel.

ON BEHALF OF THE BOARD

“Darrell A. Rader”

Darrell A. Rader
President and CEO

For more information, please contact:

Sunny Pannu – Investor Relations Manager
(778) 330 0994 or via email at pannu@minaurum.com

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this news release.

2300 – 1177 West Hastings Street
Vancouver, BC V6E 2K3

Telephone 778 330-0994
www.minaurum.com
info@minaurum.com

Cautionary Note Regarding Forward Looking Statements: Certain disclosure in this release constitute forward-looking information. In making the forward-looking statements in this release, Minaurum has applied certain factors and assumptions that are based on Minaurum’ s current beliefs as well as assumptions made by and information currently available to Minaurum. Although Minaurum considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect, and the forward-looking statements in this release are subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements. Minaurum does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

SOURCE: Minaurum Gold Inc.

ReleaseID: 446080